China 
Africa 
Explore chapters and articles related to this topic
Re-Highlighting the Potential Natural Resources for Treating or Managing the Ailments of Gastrointestinal Tract Origin
Published in Debarshi Kar Mahapatra, Cristóbal Noé Aguilar, A. K. Haghi, Applied Pharmaceutical Practice and Nutraceuticals, 2021
Vaibhav Shende, Sameer A. Hedaoo, Mojabir Hussen Ansari, Pooja Bhomle, Debarshi Kar Mahapatra
Ulcerative colitis affects most effectively the innermost lining of the colon. Although only a limited part of the bowel gets drastically affected, but, it is perceived that the whole of the colon remains inflamed. Symptoms like Crohn’s disease encompassing diarrhea and the frequent need of bowel movement is often seen along with symptoms of rectal bleeding or bloody stools, stomach pain, tiredness, and lack of appetite. The reason remains unknown despite the fact that an extraordinary immune response seems answerable for the inflammation and weight-reduction plan and stress worsens the condition.8
Crohn’s Disease
Published in Savio George Barreto, Shailesh V. Shrikhande, Dilemmas in Abdominal Surgery, 2020
Lohith Umapathi, Divya Manikandan, Govind Nandakumar
Abdominal pain is the most common presenting complaint in Crohn’s disease (60–70%), with other frequent symptoms including diarrhea (50–60%), weight loss (25–30%), fever, and fatigue. Twenty percent of patients may present with bleeding as an initial symptom. Perianal disease is seen in about 10% of patients.
Procoagulant Activity in Gastroenterology
Published in Gary A. Levy, Edward H. Cole, Procoagulant Activity in Health and Disease, 2019
Andrew J. Wakefield, Mark Hudson, Linda More
Crohn’s disease is a chronic inflammatory disease principally affecting the intestine: the disease is characterized by discontinuous full-thickness inflammation and ulceration of the bowel wall which may occur anywhere along the entire length of the gastrointestinal tract. Cutaneous,3 ocular,4 systemic,5 and mesenteric vasculitis have previously been described in patients with Crohn’s disease. Systemic thromboembolic complications are reported in 2 to 6% of patients with inflammatory bowel disease,9 rising to an incidence of 39% in postmortem studies.7 Active Crohn’s disease may be associated with an elevation of plasma fibrinogen, factor V, factor VIII, and the platelet count, and consequently the thrombotic risk has been attributed to a hypercoagulable state.7–10 However, many of these factors behave as acute-phase reactants, and elevated blood levels alone may not constitute a prothrombotic risk.
Acute orbital inflammation with loss of vision: a paradoxical adverse event associated with infliximab therapy for Crohn’s disease
Published in Orbit, 2022
David R. Jordan, John S. Y. Park, Danah Al-Breiki
Crohn’s disease is a chronic inflammatory bowel disease (IBD).24,25 Although the primary pathology in IBD is bowel inflammation, extraintestinal manifestations (EIMs) are not uncommon including ophthalmic ones that may include blepharitis, keratoconjunctivitis, peripheral corneal ulcers, episcleritis, scleritis, iridocyclitis, retinal vasculitis, choroiditis, optic neuritis/neuropathy, myositis, non-specific orbital inflammation, and dacryoadenitis.9,21,25–32 The ophthalmic EIMs may occasionally be the presenting sign of the IBD and may even respond to an anti-TNF-α blocking agents should they occur during the normal course of the Crohn’s disease.3,7,9,21,25,26,31,32 If they occur during treatment with anti-TNF-α agents, they are known as PAEs.1,4–20
IL-36: a therapeutic target for ulcerative colitis?
Published in Expert Opinion on Therapeutic Targets, 2022
Yasmina E. Hernandez Santana, Naoise Irwin, Patrick T. Walsh
Ulcerative colitis (UC) is a chronic gastrointestinal inflammatory condition characterized by inflammation of the intestinal mucosa, which can extend from the rectum to the entire length of the colon. Together with Crohn’s Disease, it represents the most frequent manifestation of Inflammatory Bowel Disease (IBD) and its most frequent symptoms include abdominal pain and diarrhea with presence of blood. Although the precise etiology of UC is poorly understood, many factors contribute to this condition including genetic background, microbiome dysbiosis, dietary and environmental factors, and dysregulated mucosal inflammation[1]. The incidence of UC is increasing among both adult and pediatric patients in developed countries, and the prevalence of disease has been estimated to range from 2.4 [2] to 294 [3] cases per 100,000 persons in Europe [4]. Furthermore, the total direct costs for UC annually are estimated at between 12.5 and 29.1 billion euros in Europe with costs associated with hospitalizations and surgery increasing with disease severity [5]. While historically, therapeutic approaches have been aimed at alleviating symptoms of disease, more recently the focus has shifted toward inhibiting specific pathways associated with dysregulated inflammation and promoting mucosal healing as a means of more effectively treating patients. Despite significant new and emerging advances in this regard, it is estimated that up to 30–40% of patients are unresponsive to currently available therapeutic options. This underlines an important need to improve and individualize treatment approaches.
Predictors of each quality of life dimension in Crohn’s disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics
Published in Scandinavian Journal of Gastroenterology, 2022
Fanny Monmousseau, Lucile Mulot, Emmanuel Rusch, Laurence Picon, David Laharie, Ginette Fotsing, Dany Gargot, Cloé Charpentier, Anthony Buisson, Caroline Trang-Poisson, Nina Dib, Véronique DES Garets, Solène Brunet-Houdard, Alexandre Aubourg
Patients with Crohn Disease (CD) may present a wide spectrum of symptoms including abdominal pain, diarrhea, fatigue, weight loss and sub-febrile conditions [1]. They can develop digestive (fistulas and abscesses, stenosis and intestinal obstructions, digestive bleeding, colorectal cancer) and extra-digestive complications (malnutrition, anemia, arthritis…). CD’s conventional treatments are based on aminosalicylates, corticosteroids and immunomodulators (Azathioprine, Methotrexate…) and prescribed according to the location and the activity of the disease [2]. Anti-TNFs, approved for moderate to severe disease, are increasingly prescribed in the first line of severe forms. Until recently, two drugs were available in Europe: adalimumab administered via subcutaneous injection (SC) every fourteen days, and infliximab via intravenous infusion (IV) every eight weeks at the hospital. The first subcutaneous version of the biosimilar infliximab is now available.